Brought to you by 
Pain company Afferent completes $23mm Series A round
22 Dec 2020
Executive Summary
Third Rock Ventures and Pappas Ventures have the led the Series A financing of chronic pain start-up Afferent Pharmaceuticals, which received $23mm. Domain Associates and New Leaf Venture Partners also invested. Each VC is represented on the company's board.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pain company Afferent completes $23mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice